Share

Join the EORTC Quality of Life Group at ISOQOL Annual Conference 2022

Brussels, 6th October 2022: The EORTC Quality of Life Group (QLG) is pleased to be taking part this year again in the annual conference of the International Society for Quality of Life Research (ISOQOL), which will be held from 19th to 22nd October in Prague (Czech Republic).

ISOQOL is a global community of researchers, clinicians, health care professionals, industry professionals, consultants, and patient research partners who aim to advance research around health-related quality of life (HRQoL) and patient-reported outcomes (PRO) in cancer patients.

Quality of Life in cancer research

The EORTC QLG is proud to be once again well-represented at the ISOQOL conference, with eleven abstracts being presented on this occasion, of which seven are oral presentations. These will address latest developments on QLG projects such as the computerized adaptive testing (CAT), the Common Terminology Criteria for Adverse Events (CTCAE) mapping, the development of an interpretation guideline for the EORTC PRO measures, and many more. Please find below an outline of QLG abstracts to be presented at the ISOQOL conference 2022.

The EORTC QLG Chair, Dr Jaap Reijneveld, noted that our work highlights the importance of quality of life for cancer patients, stating : “We have come a long way, with quality of life being considered in cancer research only since a few decades”, adding that: “our group can be proud to having so many abstracts presented at such an important conference in this field, positioning EORTC QLG at the forefront of research on quality of life in cancer”.

In addition, we are very happy to be hosting a booth on this occasion, to have the opportunity to answer your questions about the QLG and its projects. Please come and visit us in Prague, and get to know more about the group’s latest developments!

Oral sessions

Development of standard CAT-settings for simplified use of the EORTC CAT core
Morten Petersen, Hugo Vachon, Mogens Groenvold
Oral Session 102: Methodological Research (102.1)
Presenting author: Morten Petersen
Date: Thursday 20th October, 1:45PM-3:15PM

Does baseline health-related quality of life scores (QLQ-C30) add prognostic value beyond clinical measures and improve prognostic accuracy in cancer RCTs?
Abigirl Machingura, Jammbe Musoro, Mekdes Taye, Jolie Ringash, Madeline Pe, Corneel Coens, Francesca Martinelli, Dongsheng Tu, Ethan Basch, Yvonne Brandberg, Mogens Grønvold, Alexander Eggermont, Fatima Cardoso, Jan Van Meerbeeck, Winette T.A. van der Graaf, Martin Taphoorn, Jaap C. Reijneveld, Riccardo Soffietti, Jeff Sloan, Galina Velikova, Henning Flechtner, Andrew Bottomley
Oral Brief Session 204: Methods (B204.5)
Presenting author: Abigirl Machingura
Date: Friday 21st October, 1:20PM-2:50PM

Synthesis of anchor-based minimally important differences (MID) for the EORTC QLQ-C30 scales across nine cancer sites
Jammbe Musoro, Corneel Coens, Mirjam AG Sprangers, Yvonne Brandberg, Mogens Groenvold, Kim Cocks, Galina Velikova, Linda Dirven, Elfriede Greimel, Susanne Singer, Pogoda Katarzyna, Eva M. Gamper, Samantha Sodergren, Alexander Eggermont, Michael Koller, Madeleine T King, Andrew Bottomley
Oral Session 207: Defining Meaningful Change (207.1)
Presenting author: Jammbe Musoro
Date: Friday 21st October, 3:40PM-5:10PM

Minimally Important Differences (MID) by Anchoring to Patients’ Rating of Change in Oncology: A Systematic Review
Pegah Rousta, Corneel Coens, Madeline Pe, Andrew Bottomley, Haneen Abaza, Fábio Cardoso-Borges, Yannick Eller, Angelos Kassianos, Alizé Rogge, Sunil Shrestha, Mogens Grønvold, Mirjam Sprangers, Madeline King, Yvonne Brandberg, Alexander Eggermont, Bernhard Holzner, Galina Velikova, Jaap Reijneveld, Henning Flechtner, Eva Greimel, Katarzyna Pogoda, Linda Dirven, Jammbe Musoro
Oral Session 207: Defining Meaningful Change (207.2)
First and presenting author: Corneel Coens
Date: Friday 21st October, 3:40PM–5:10PM

Establishing thresholds for clinical importance for EORTC questionnaire modules for specific cancer patient populations
Micha Johannes Pilz, Juan I. Arraras, Andrew Bottomley, Fabio Efficace, Mogens Groenvold, Bernhard Holzner, Marieke van Leeuwen, John Ramage, Teresa Young, Johannes M. Giesinger
Oral Session 207: Defining Meaningful Change (207.4)
First and presenting author: Micha Johannes Pilz
Date: Friday 21st October, 3:40PM–5:10PM

Do we measure the right thing? – Lack of evidence for the content validity of health-related quality of life questionnaires for children with cancer
Maria Rothmund, Andreas Meryk, Gerhard Rumpold, Roman Crazzolara, Samantha Sodergren, Anne-Sophie Darlington, David Riedl
Oral Session 302: Qualitative methods in the development and application of PROs (302.4)
Presenting author: Maria Rothmund
Date: Saturday 22nd October, 4:10PM-5:40PM

Phase I of the Development of an EORTC QOL Module for Patients with Metastatic Melanoma
Mees D. Egeler, Marieke van Leeuwen, Hans Eriksson, Louis Fox, Mieke van Hemelrijck, Michael Jefford, Julia Lai-Kwon, Ofir Morag, Galia Pesah, Anne Rogiers, Samantha Serpentini, Helena Tufvesson Stiller, Nathalie Vanlaer, Alexander C.J. van Akkooi, Lonneke V. van de Poll-Franse
First and presenting author: Mees D. Egeler
Oral Session 304: Measurement Considerations in Clinical Care II
Date: Saturday 22nd October, 4:10PM

Poster presentations

The development of an interpretation guideline for the European Organization for Research and Treatment of Cancer (EORTC) patient-reported outcome measures
Monika Sztankay, Daniela Krepper, Caroline Martini, Lisa Wintner, Teresa Young, Andrew Bottomley, Jammbe Musoro, Johannes M. Giesinger
Session: Thursday Morning Poster Presentations: Slot 2
Presentation number: 3006
Presenting author: Monika Sztankay
Date: Thursday 20th October, 10:25AM-10:40AM

Clinical characteristics of EORTC item list implementation: A summary based on four years of Item Library use
Claire Piccinin, Alexandra Gilbert, Mogens Groenvold, Dagmara Kuliś, Galina Velikova, Andrew Bottomley
Session: Thursday Afternoon Poster Presentations: Slot 7
Presentation number: 3047
Presenting author: Claire Piccinin
Date: Thursday 20th October, 3:45PM-4:00PM

Interpretation of European Organisation of Research and Treatment of Cancer (EORTC) patient-reported outcome data: the stakeholder perspective on challenges and information needs
Monika Sztankay, Daniela Krepper, Lisa Wintner, Johannes M. Giesinger
Session: Friday Afternoon Poster Presentations: Slot 1
Presentation number: 3087
Presenting author: Monika Sztankay
Date: Friday 21st October, 1:20PM-1:35PM

Patient-reported outcome measures in cancer patients: content comparison of the EORTC CAT Core, EORTC QLQ-C30, SF-36, FACT-G, and selected PROMIS measures using the International Classification of Functioning, Disability and Health
Micha J. Pilz, Emma Lidington, Claire Piccinin, Juan I. Arraras, Mogens Groenvold, Bernhard Holzner, Marieke van Leeuwen, Morten Aa. Petersen, Heike Schmidt, Teresa Young, Johannes M. Giesinger
Session: Friday Afternoon Poster Presentations: Slot 3
Presentation number: 3099
Presenting author: Johannes M. Giesinger
Date: Friday 21st October, 2:00PM-2:15PM

Plenary session

We have the pleasure to support the Plenary session number 2 “Cutting Edge Research Plenary, which will feature innovative research from ISOQOL abstract submissions.

Speakers include:

  • Berend Terluin, MD PhD, Amsterdam University Medical Center, Amsterdam, the Netherlands
  • Paul Schneider, MD MSc, University of Sheffield, Sheffield, United Kingdom
  • Tolulope Sajobi, PhD, University of Calgary, Calgary, Alberta, Canada
  • Carolyn Schwartz, ScD, DeltaQuest Foundation and Tufts University School of Medicine, Concord, Massachusetts, United States

Date: Thursday 20th October, 10:50AM-12:00PM

Find out more about ISOQOL and the conference programme here: www.isoqol.org.
More information about the EORTC QLG participation to ISOQOL 2022 is also available here.

About the Quality of Life Group

The Quality of Life Group (QLG) strives to improve health-related quality of life (HRQoL) of cancer patients, through dedicated research and the use of HRQoL measures within cancer clinical trials and clinical practice. HRQoL constitutes an important aspect of cancer research and care: it gives a voice to patients, putting their experience at the forefront. The QLG is part of the European Organisation for Research and Treatment of Cancer (EORTC).

For further information, please visit the QLG website: qol.eortc.org

About EORTC

The European Organisation for Research and Treatment of Cancer (EORTC) is a non-governmental, non-profit organisation, which unites clinical cancer research experts, throughout Europe, to define better treatments for cancer patients to prolong survival and improve quality of life. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life, its activities are coordinated from EORTC Headquarters, a unique international clinical research infrastructure, based in Brussels, Belgium.
For further information, please visit the EORTC website: www.eortc.org

Contact

Caroline Hance (EORTC QLG)
caroline.hance@eortc.org

Back to news list

Related News

  • Meet the new EORTC Board

  • We are pleased to announce the release of the EORTC 2023 Annual Report

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)